SE0103838D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103838D0
SE0103838D0 SE0103838A SE0103838A SE0103838D0 SE 0103838 D0 SE0103838 D0 SE 0103838D0 SE 0103838 A SE0103838 A SE 0103838A SE 0103838 A SE0103838 A SE 0103838A SE 0103838 D0 SE0103838 D0 SE 0103838D0
Authority
SE
Sweden
Prior art keywords
alpha
drug
formulation
methylpropiono
fluorophenylsulphonyl
Prior art date
Application number
SE0103838A
Other languages
Swedish (sv)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103838A priority Critical patent/SE0103838D0/en
Publication of SE0103838D0 publication Critical patent/SE0103838D0/en
Priority to PCT/GB2002/005158 priority patent/WO2003043630A1/en
Priority to AU2002339169A priority patent/AU2002339169A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical formulation comprising the drug 4'-cyano-alpha',alpha',alpha'-trifluoro-3-4-fluorophenylsulphonyl-2-hydroxy-2-methylpropiono-m-toluidide in a solid dispersion with PVP, the formulation further comprising an anti-oestrogen eg, tamoxifen citrate and/or an aromatase inhibitor eg, anastrozole. The invention also relates to a pharmaceutical dose of the drug and anti-oestrogen/aromatase inhibitor provided by such a formulation. An advantage is the treating and/or preventing of at least one side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido, while increasing the bioavailability of the drug reducing inter-patient variability in plasma concentrations of the 4'-cyano-alpha',alpha',alpha'-trifluoro-3-4-fluorophenylsulphonyl-2-hydroxy-2-methylpropiono-m-toluidide enhancing the storage stability of the drug and/or treating and/or reducing the risk of prostate cancer in a patient.
SE0103838A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103838D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
PCT/GB2002/005158 WO2003043630A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
AU2002339169A AU2002339169A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103838D0 true SE0103838D0 (en) 2001-11-16

Family

ID=20286022

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103838A SE0103838D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (3)

Country Link
AU (1) AU2002339169A1 (en)
SE (1) SE0103838D0 (en)
WO (1) WO2003043630A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
JP4777887B2 (en) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション Fluoro-substituted omegacarboxyaryl diphenylureas for the treatment and prevention of diseases and conditions
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP5243247B2 (en) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド Process for improving the properties of spray-dried powders and granulated materials and products produced thereby
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
CN104146974B (en) * 2014-08-14 2016-09-07 杭州华东医药集团新药研究院有限公司 A kind of compositions containing letrozole and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318371A1 (en) * 1993-05-28 1994-12-01 Schering Ag Agent containing a compound with antiandrogenic and a compound with competitive, progesterone-antagonistic effect
ES2307482T3 (en) * 1999-02-10 2008-12-01 Pfizer Products Inc. SOLID PHARMACEUTICAL DISPERSIONS.
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
CZ20032225A3 (en) * 2001-02-27 2003-11-12 Astrazeneca Ab Pharmaceutical formulation
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Also Published As

Publication number Publication date
WO2003043630A1 (en) 2003-05-30
AU2002339169A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IS6970A (en) Solid formulation comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide and PVP
AR032912A1 (en) PHARMACEUTICAL FORMULATION
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
BRPI0413427A (en) active pyridylpyrrole derivatives as kinase inhibitors
CY1115782T1 (en) PHARMACEUTICAL COMPOSITIONS FOR CANCER TREATMENT
PA8606201A1 (en) PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
CY1115056T1 (en) Pharmaceutical Compositions Containing Fentanyl For Intranasal Administration
SE0103839D0 (en) Pharmaceutical formulation & product
EP1423107A4 (en) Fatty alcohol drug conjugates
NO20034204D0 (en) Pharmaceutical combinations for the treatment of cancer
ATE309798T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
MXPA06000302A (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
ATE396986T1 (en) PYRIMIDYLPYRROLE DERIVATIVES THAT ACTION AS KINASE INHIBITORS
HK1068606A1 (en) Novel aminobenzoephenones
BR0207443A (en) Method and dosage form for the treatment of tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
PE20040990A1 (en) COMBINATIONS OF ERB B KINASE INHIBITORS AND ANTINEOPLASTIC DRUGS
SE0103838D0 (en) Pharmaceutical formulation & product
SE0103424D0 (en) Pharmaceutical formulation
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BRPI0407611A (en) anti-cancer agent comprising protein lk8 as an active ingredient
NO20064753L (en) combination therapy
PE20031047A1 (en) TREATMENT OF POST-MENOPAUSAL PATIENTS IN PATIENTS WITH BREAST CANCER
SE0102887D0 (en) New formulation
NO20026032D0 (en) Farnesyltransferase inhibiting 1,2-annealed quinoline enantiomer
HK1061530A1 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy.